FDA approves GSK's Hibsago for chronic hepatitis B in certain adults
The US Food and Drug Administration has approved GSK's Hibsago (bepirovirsen) for a defined group of adults with chronic hepatitis B, GSK said.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
GSK said the FDA approved Hibsago (bepirovirsen) to be used alongside nucleos(t)ide analogue therapy in certain adults with chronic hepatitis B. The approval covers patients without cirrhosis, with HBsAg at or below 3000 IU/mL, who have taken nucleos(t)ide analogues for at least six months and have suppressed HBV DNA.
The drug received Priority Review and Breakthrough Therapy designation. In trials, 19% of patients achieved functional cure, compared with under 1% on standard care alone. The label carries boxed warnings on liver and platelet risks.
why it matters
The approval opens a large US market for GSK's first-in-class antisense oligonucleotide. Investors will watch launch pace, payer coverage and real-world safety data to judge the drug's commercial potential, as the label limits the initial patient pool.
market impact
GSK: a new US revenue stream, though narrow labeling and safety warnings may temper expectations
tags
instruments
sources
- GSK plc (GSK) Gets FDA Approval for Hibsago in CHB — TradingView, 20 October 2026 at 23:58 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗